Form 4 for STLN Starling Oncology, Inc.
Accepted 2025-04-02 00:00:00 ET · period of report 2025-03-31 · accession 0001799191-25-000021 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-04-02 | 2025-03-31 | STLN | Carter Robert Ross | CFO | A - Grant | $0.00 | +197.4K | 236.8K | +501% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-03-31 | A | A | 197,368 | $0.00 | 236,775 | D | — | — | (F1) Represents RSU awards with 1/4th of the RSUs vesting on the first anniversary of the Vesting Commencement Date, with the remaining RSUs vesting in three equal annual installments beginning on the first anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. |